Literature DB >> 24891360

Second-generation ALK inhibitors: filling the non "MET" gap.

Suresh S Ramalingam1, Fadlo R Khuri2.   

Abstract

Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provide new options for the management of ALK-positive NSCLC. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24891360      PMCID： PMC4551422          DOI： 10.1158/2159-8290.CD-14-0410

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors:  Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Authors:  Luc Friboulet; Nanxin Li; Ryohei Katayama; Christian C Lee; Justin F Gainor; Adam S Crystal; Pierre-Yves Michellys; Mark M Awad; Noriko Yanagitani; Sungjoon Kim; AnneMarie C Pferdekamper; Jie Li; Shailaja Kasibhatla; Frank Sun; Xiuying Sun; Su Hua; Peter McNamara; Sidra Mahmood; Elizabeth L Lockerman; Naoya Fujita; Makoto Nishio; Jennifer L Harris; Alice T Shaw; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2014-03-27       Impact factor: 39.397

4.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

5.  The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Authors:  E Normant; G Paez; K A West; A R Lim; K L Slocum; C Tunkey; J McDougall; A A Wylie; K Robison; K Caliri; V J Palombella; C C Fritz
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

6.  Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Authors:  Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

7.  A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.

Authors:  Mark A Socinski; Jonathan Goldman; Iman El-Hariry; Marianna Koczywas; Vojo Vukovic; Leora Horn; Eugene Paschold; Ravi Salgia; Howard West; Lecia V Sequist; Philip Bonomi; Julie Brahmer; Lin-Chi Chen; Alan Sandler; Chandra P Belani; Timothy Webb; Harry Harper; Mark Huberman; Suresh Ramalingam; Kwok-Kin Wong; Florentina Teofilovici; Wei Guo; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2013-04-03       Impact factor: 12.531

8.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

9.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

10.  CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Authors:  Takashi Seto; Katsuyuki Kiura; Makoto Nishio; Kazuhiko Nakagawa; Makoto Maemondo; Akira Inoue; Toyoaki Hida; Nobuyuki Yamamoto; Hiroshige Yoshioka; Masao Harada; Yuichiro Ohe; Naoyuki Nogami; Kengo Takeuchi; Tadashi Shimada; Tomohiro Tanaka; Tomohide Tamura
Journal:  Lancet Oncol       Date:  2013-04-30       Impact factor: 41.316
  10 in total
  3 in total

Review 1.  Molecular testing in lung cancer in the era of precision medicine.

Authors:  Helmut H Popper; Ales Ryska; József Tímár; Wlodzimierz Olszewski
Journal:  Transl Lung Cancer Res       Date:  2014-10

Review 2.  Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance.

Authors:  Zilan Song; Meining Wang; Ao Zhang
Journal:  Acta Pharm Sin B       Date:  2015-01-24       Impact factor: 11.413

Review 3.  Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.

Authors:  Ravi Salgia
Journal:  Expert Rev Mol Diagn       Date:  2016-05-26       Impact factor: 5.225
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.